The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.
The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.
Patent No.:
Date of Patent:
Jan. 05, 2016
Filed:
Jun. 06, 2013
Applicant:
Merrimack Pharmaceuticals, Inc., Cambridge, MA (US);
Inventors:
Joseph G. Reynolds, North Andover, MA (US);
Kenneth J. Olivier, Jr., Attleboro, MA (US);
Bart S. Hendriks, Belmont, MA (US);
Thomas Wickham, Groton, MA (US);
Stephan Klinz, Norwood, MA (US);
Elena Geretti, Cambridge, MA (US);
Assignee:
MERRIMACK PHARMACEUTICALS, INC., Cambridge, MA (US);
Primary Examiner:
Assistant Examiner:
Int. Cl.
CPC ...
G01N 33/566 (2006.01); A61K 47/42 (2006.01); A61K 31/7042 (2006.01); A61K 47/48 (2006.01); A61K 31/704 (2006.01);
U.S. Cl.
CPC ...
A61K 47/42 (2013.01); A61K 31/704 (2013.01); A61K 31/7042 (2013.01); A61K 47/48569 (2013.01); A61K 47/48823 (2013.01); G01N 33/566 (2013.01);
Abstract
Methods for determining dosage of HER2-targeted anthracycline-containing immunoliposomes are disclosed, as are methods of treating cancer patients with HER2-positive tumors using dosages so determined. Upon administration, the dosages share the low cardiotoxicity profile of standard dosages of non-immunoliposomal (untargeted), anthracycline-containing liposomes.